Phase 1 Risk Clinical Trials
47 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 47 trials
Recruiting
Phase 1Phase 2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Acute Lymphoblastic LeukaemiaHigher Risk Myelodysplastic SyndromesAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting
Phase 1
Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
Breast ReconstructionGenetic PredispositionPerfusion; Complications+1 more
Duke University25 enrolled1 locationNCT07264790
Recruiting
Phase 1
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Acute Myeloid LeukemiaR/R AMLR/R HR-MDS+1 more
Genmab78 enrolled6 locationsNCT07384715
Recruiting
Phase 1
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Pancreatic CancerHigh-Risk Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins37 enrolled1 locationNCT05013216
Recruiting
Phase 1
Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)
Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
Nantes University Hospital12 enrolled1 locationNCT05749276
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaNon-Hodgkin LymphomaMultiple Myeloma+3 more
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 1
A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969
Healthy Subjects (HS)Obese Adult Participants at Risk of Cardiovascular Disease
InSilico Medicine Hong Kong Limited100 enrolled1 locationNCT07581431
Recruiting
Phase 1Phase 2
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeRecurrent Acute Myeloid Leukemia+5 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT04047641
Recruiting
Phase 1Phase 2
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Clinical High Risk for Psychosis (CHR)
Monument Therapeutics Limited150 enrolled15 locationsNCT07226895
Recruiting
Phase 1Phase 2
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
ParagangliomaPheochromocytomaSolid Tumor Cancer+19 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 1Phase 2
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
High-Risk Localized Soft Tissue Sarcoma
Fudan University52 enrolled1 locationNCT05774275
Recruiting
Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center38 enrolled1 locationNCT03896269
Recruiting
Phase 1Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center52 enrolled1 locationNCT04128748
Recruiting
Phase 1Phase 2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
Prostate CancerLocalized Prostate CarcinomaHigh-risk Prostate Cancer+2 more
Thomas Hope45 enrolled1 locationNCT07054346
Recruiting
Phase 1Phase 2
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+1 more
Beijing Biotech36 enrolled1 locationNCT07502287
Recruiting
Phase 1
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Chronic Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)+1 more
Crossbow Therapeutics, Inc.72 enrolled11 locationsNCT06994676
Recruiting
Phase 1
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Stage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8+1 more
University of California, Davis30 enrolled1 locationNCT05843448
Recruiting
Phase 1Phase 2
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
High Risk Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center116 enrolled1 locationNCT03214562